ライフサイエンスコーパス: extranodal

1 Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy

2 Extranodal abdominal sites included liver (53%), small b

3 had atrioventricular dissociation ruling out extranodal accessory pathways, including atriofascicular

4 noclonal in 33%, 63%, and 56% of polymorphic extranodal and nodal LPD cases and DLBCL, respectively.

5 In earlier studies, we found that primary extranodal and widely disseminated aggressive non-Hodgki

6 tion and cloning of breakpoints in a case of extranodal ascitic B-cell lymphoma with a t(1;14)(q21;q3

7 ssociated with the development of aggressive extranodal B-cell non-Hodgkin's lymphomas.

8 e frequently (P = 0.02) compared to nodal or extranodal cases, alluding to distinct immunopathogeneti

9 ulterior transformation and accounts for the extranodal clinical presentation and biology of these tu

10 extranodal sites (P = .005), both nodal and extranodal disease (P = .002), high International Progno

11 was associated with younger age (P=0.0016), extranodal disease (P=0.019), graft organ involvement (P

12 ese individuals have presented with advanced extranodal disease and CD4+ lymphocyte counts of less th

13 e significant predictors of poor OS and EFS: extranodal disease at first relapse, presence of mediast

14 Extranodal disease at relapse was associated with inferi

15 f these factors also predicted for poor PFS (extranodal disease at time of first relapse and presence

16 Upstaging by extranodal disease in bone marrow (92), lung (11), or mu

17 Extranodal disease including grafted organ involvement w

18 advanced stage, aggressive presentation, and extranodal disease is higher.

19 Extranodal disease occurred at presentation in 70% and a

20 racy of (18)F-FDG PET/MRI for both nodal and extranodal disease was compared with that of (18)F-FDG P

21 Extranodal disease was present in 30 patients (86%), wit

22 ents (87%) presented with nodal disease, but extranodal disease was present in 62%.

23 symptoms, bulky disease, advanced stage, or extranodal disease), relapse.

24 Of 19 complete responders, 84% had extranodal disease, 47% had CD4 < 100/muL, and 47% had V

25 on rate, B symptoms, large mediastinal mass, extranodal disease, and 3 or more lymph nodes) was stati

26 the study, 46% had stage II disease, 42% had extranodal disease, and 58% were more than 60 years of a

27 s (83%) had stage III to IV disease, 92% had extranodal disease, and 75% had > or = three sites of di

28 ed with improved outcome, whereas older age, extranodal disease, and acute graft-vs-host disease pred

29 y reported that remission duration < 1 year, extranodal disease, and B symptoms before salvage chemot

30 ICE that predicted for outcome: B symptoms, extranodal disease, and complete remission duration of l

31 All had extranodal disease, but only one had bone marrow involve

32 ly present with progressive lymphadenopathy, extranodal disease, or both and require therapy.

33 was present in 24%, and 76% of patients had extranodal disease.

34 maging should be considered in patients with extranodal disease.

35 nd to be more sensitive than CT at detecting extranodal disease.

36 sented with lymphadenopathy and 11% also had extranodal disease.

37 ation of the treatment response of nodal and extranodal diseases in patients with malignant lymphomas

38 MCD/C5s manifest prominent extranodal dissemination and similarities with primary e

39 f haematological cancers where lymphatic and extranodal dissemination are poor prognostic factors.

40 lation in these tumors correlated with their extranodal dissemination status.

41 loped incorporating new histologic entities, extranodal dissemination, improved diagnostic methods, a

42 eased nodal disease and increased widespread extranodal dissemination.

43 l lymphoma (DLBCL), which is associated with extranodal dissemination.

44 ressive B cell lymphomas frequently manifest extranodal distribution and carry somatic mutations in t

45 med, the latter consisting of both nodal and extranodal DLBCL (nDLBCL and enDLBCL), to identify a "CN

46 Other extranodal DLBCL involving the breast, adrenal glands, a

47 DUSP4 is aberrantly methylated in nodal and extranodal DLBCL, irrespective of ABC or GCB subtype, re

48 3 siblings with PMBCL and their cousin with extranodal DLBCL.

49 The extranodal expansion of Bc.DLFL1 lymphoma within the ome

50 ients with tumor size greater than 4.0 cm or extranodal extension >/= 2 mm experienced rates of isola

51 ne to three involved nodes and large tumors, extranodal extension >/= 2 mm, or inadequate axillary di

52 ended for head and neck cancer patients with extranodal extension (ENE) and/or positive margins, but

53 Extranodal extension (ENE) in oral cavity squamous cell

54 Extranodal extension (ENE) is a biomarker in oropharynge

55 Extranodal extension (ENE) is a well-established poor pr

56 Extranodal extension (ENE) is an adverse feature in huma

57 to undergo axillary lymph node dissection if extranodal extension (ENE) is present.

58 The extranodal extension (ENE) of nodal metastasis involves

59 HPV-positive OPSCC without obvious clinical extranodal extension (ENE) who underwent definitive TORS

60 Nodal stage, tonsillectomy history, extranodal extension (ENE).

61 metastases, possibly due to the inclusion of extranodal extension (ENE).

62 Extranodal extension (HR, 1.41; 95% CI, 1.20 to 1.65; P

63 number of abnormal LN, and imaging-detected extranodal extension (iENE).

64 Extranodal extension (OR, 0.2; 95% CI, 0.04-0.8), lymph

65 P < 0.001), SLN metastasis size (P < 0.001), extranodal extension (P < 0.001), tumor size (P = 0.001)

66 P <.001), tumor size (P <.001), and >/= 2-mm extranodal extension (P <.001) were also predictive of L

67 and P = .017, respectively), and absence of extranodal extension (P = .001 and P = .004, respectivel

68 res to predict the probability of pathologic extranodal extension (pENE) in patients with oropharynge

69 , and 4552 patients (31.5%) had pathological extranodal extension (pENE).

70 consensus on reporting of histology detected extranodal extension and on nodal sampling.

71 Patients were stratified by the presence of extranodal extension and smoking status (<10 packs per y

72 d diagnostic features for histology detected extranodal extension and soft tissue metastasis.

73 Furthermore, if imaging detected extranodal extension could be identified reliably before

74 Compelling evidence suggests that extranodal extension detected on radiological imaging is

75 ensus recommendations for histology detected extranodal extension diagnostic criteria.

76 breast cancer appears to be consistent with extranodal extension of tumor into perinodal fat.

77 Extranodal extension of tumour on histopathology is know

78 Detection of extranodal extension on histopathology in surgically tre

79 ologic T stage, number of positive nodes, or extranodal extension on pathological analysis of surgica

80 aneous integrated boost to nodal levels with extranodal extension to 36 Gy in 1.8-Gy fractions twice

81 nvolved node was 2.0 cm (range, 0.4-7.0 cm); extranodal extension was present in 69 patients (45%).

82 No extranodal extension was reported.

83 imum SLN metastasis size and the presence of extranodal extension were recorded.

84 Cohort B included patients with extranodal extension who received the same treatment plu

85 l sites, no B symptoms, mediastinal bulk, or extranodal extension) enrolled between March 3, 2000, an

86 The MVA identified pT3-4, pathologic extranodal extension, and engraftment as predictors of L

87 for factors such as nodal size, laterality, extranodal extension, margin status, and adjuvant treatm

88 l trial, the presence of high-risk features (extranodal extension, positive margins, or both) was ass

89 y tumor size, lymphovascular space invasion, extranodal extension, the number of involved SLNs, the n

90 nt, in conjunction with pT3-4 and pathologic extranodal extension, was associated with improved progn

91 etation, and reporting of histology detected extranodal extension, which has contributed to conflicti

92 tional resource for grading imaging detected extranodal extensions.

93 We used microdissection of such extranodal follicles to analyze the colonizing T cells.

94 reported a 36-year-old male patient with the extranodal form of Rosai-Dorfman disease, presenting wit

95 To examine their role in extranodal GC reactions, CD8 T cells were depleted in hu

96 while p73 modulated tumor dissemination and extranodal growth.

97 ose tissue microenvironment to support their extranodal growth.

98 ients with EMZL (84%) presented with stage E-extranodal (IE), however only 16% had an advanced stage.

99 phoid microstructures that could be sites of extranodal immune activation.

100 tely, TBL1XR1 alterations lead to a striking extranodal immunoblastic lymphoma phenotype that mimics

101 t with CD11c(+) dendritic cells, whereas the extranodal infiltration occurred selectively in the mese

102 but it is unknown whether MASH could promote extranodal infiltration of lymphoma.

103 Extranodal, intracranial disease is uncommon.

104 (+)IGF1R(+)CSF1R(+) LC phenotypes, including extranodal invasion and chemoresistance.

105 high-stage (III and IV) disease and 61% had extranodal involvement at presentation, including 25% wi

106 lapse within 12 months of initial therapy or extranodal involvement at the start of pre-transplantati

107 l EBV(+) diffuse large B-cell lymphomas with extranodal involvement developing in the context of graf

108 Frequently, there is extranodal involvement including the gastrointestinal tr

109 Extranodal involvement is more common than splenic or no

110 If extranodal involvement occurred, 2 splenic lesions, 2 sk

111 CNS involvement in PMLCL is associated with extranodal involvement other than bone marrow and may re

112 In the multivariable analyses, extranodal involvement was associated with worse OS (haz

113 Other sites of extranodal involvement were observed in 50% of cases.

114 IIB with mediastinum/thorax ratio > 0.33 or extranodal involvement) age 16-60 years were prospective

115 CD30-positivity, nodal disease with frequent extranodal involvement, advanced stage, and an excellent

116 elevated erythrocyte sedimentation rate, 21% extranodal involvement, and 56% > 2 involved lymph node

117 years, 75% had stage III/IV disease, 67% had extranodal involvement, and 64% received rituximab.

118 , MYC rearrangement, protein expression, and extranodal involvement, and review our clinical practice

119 with B symptoms, and 40% of patients showed extranodal involvement.

120 s (25%) had staging laparotomy; 34 (19%) had extranodal involvement.

121 d is characterized by frequent cutaneous and extranodal involvement.

122 apidly progressive tumors with high rates of extranodal involvement.

123 s; race (white/nonwhite); nodal involvement; extranodal involvement; number of extranodal sites; spec

124 However, a diagnosis of primary extranodal large B-cell lymphoma was returned.

125 and primary testicular lymphomas (PTLs) are extranodal large B-cell lymphomas (LBCLs) with inferior

126 d primary testicular lymphoma (PTL) are rare extranodal large B-cell lymphomas with similar genetic s

127 ECT enabled the identification of additional extranodal lesions (hepatic, muscular, and gastric) in o

128 h risk factors of large mediastinal mass and extranodal lesions).

129 V), with especially bone marrow and liver as extranodal localizations.

130 alignancies that can arise in lymph nodes or extranodal locations, including immune-privileged sites.

131 Sixteen of 21 cases of polymorphic extranodal LPD were classified as EBV(+) mucocutaneous u

132 id tissue (MALT) lymphoma is the most common extranodal lymphoid cell neoplasia; it frequently follow

133 of all tumors examined and clear evidence of extranodal lymphoid follicles with germinal center-like

134 The significance of this extranodal lymphoid neogenesis is unknown.

135 e and infiltrating lymphocytes in regulating extranodal lymphoid neogenesis.

136 id tissue (MALT) lymphoma is the most common extranodal lymphoid neoplasm.

137 ymphoproliferative disorders are a family of extranodal lymphoid neoplasms that arise from mature pos

138 mal cellular proliferations characterized as extranodal lymphoma and a proliferative mesenchymal lesi

139 This paper is part of the International Extranodal Lymphoma Study Group (IELSG) 26 prospective s

140 The International Extranodal Lymphoma Study Group (IELSG) 26 study was des

141 n the international randomized International Extranodal Lymphoma Study Group 19 (IELSG-19) trial.

142 The International Extranodal Lymphoma Study Group 19 phase 3 trial showed

143 The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an

144 ternational randomised phase 2 International Extranodal Lymphoma Study Group-32 (IELSG32) trial, HIV-

145 hese DLBCL subtypes and various indolent and extranodal lymphoma types, suggesting a shared pathogene

146 ry adrenal lymphomas are a very rare type of extranodal lymphoma, and they usually are found bilatera

147 TL) is a rare, clinically aggressive form of extranodal lymphoma.

148 dissemination and similarities with primary extranodal lymphomas (PENLs).

149 Extranodal lymphomas can occur in almost every organ, an

150 ions, as data on efficacy in nodal and other extranodal lymphomas have been extrapolated to PTL.

151 ll lymphomas (CTCLs) are a family of primary extranodal lymphomas of mature CD4(+), skin-homing or sk

152 2% of non-Hodgkin lymphomas (NHLs) and 8% of extranodal lymphomas.

153 ts for 0.4% of breast malignancies and 2% of extranodal lymphomas.

154 intestinal tract is the most common site for extranodal lymphomas.

155 LC (73%) with REL amplification were primary extranodal lymphomas.

156 s a progression-associated marker of primary extranodal lymphomas.

157 d as the gold standard method for diagnosing extranodal lymphomas.

158 al nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous malignancy that affects the brai

159 and whether it is clinically different from extranodal MALT-type lymphoma, we compared the clinical

160 Extranodal manifestations were common in stage I and in

161 Because of gastral and extranodal manifestations, guideline-compatible diagnost

162 Extranodal marginal zone (MZ) B-cell lymphomas of the mu

163 The most frequent lymphoma subtypes were extranodal marginal zone B-cell lymphoma (EMZL) (n = 177

164 Extranodal marginal zone B-cell lymphoma (EMZL) was the

165 homa Study Group classification of lymphoma, extranodal marginal zone B-cell lymphoma (MZL) of mucosa

166 4-year-old patient, who had liver granuloma, extranodal marginal zone B-cell lymphoma, and autoimmune

167 s the majority of follicle center lymphomas, extranodal marginal zone B-cell lymphomas, and immunocyt

168 d in the monocytoid and plasmacytic cells in extranodal marginal zone lymphoma (15 of 16 cases).

169 The most frequent subtype was extranodal marginal zone lymphoma (EMZL) (68.4% [180 of

170 Extranodal marginal zone lymphoma (EMZL) has a very indo

171 The histologic subtype was extranodal marginal zone lymphoma (EMZL) in 51 patients

172 Extranodal marginal zone lymphoma (EMZL) was the most fr

173 hemistry were most consistent with pulmonary extranodal marginal zone lymphoma (ENMZL; Fig 2 ).

174 aldenstrom's macroglobulinemia (n = 2, 11%), extranodal marginal zone lymphoma (n = 2, 11%), plasmabl

175 enty-five percent of the cases reported were extranodal marginal zone lymphoma of mucosa-associated l

176 Extranodal marginal zone lymphoma of mucosa-associated l

177 re no widely accepted prognostic indices for extranodal marginal zone lymphoma of mucosa-associated l

178 optimal systemic treatment of patients with extranodal marginal zone lymphoma of mucosa-associated l

179 genetic alteration among nodal, splenic, and extranodal marginal zone lymphoma types has yet to be de

180 Extranodal marginal zone lymphoma was the predominant (7

181 CL (37% low-grade non-Hodgkin lymphoma, 27% extranodal marginal zone lymphoma).

182 fusion transcripts were detected in 12 of 57 extranodal marginal zone lymphomas (21%), but in none of

183 Extranodal marginal zone lymphomas (EMZL) are the most c

184 gest that t(11;18)(q21;q21) is restricted to extranodal marginal zone lymphomas and that these tumors

185 le cell, five follicular, five Burkitt, five extranodal marginal zone lymphomas of mucosa-associated

186 comparison, 16 follicular lymphomas (FLs), 9 extranodal marginal zone lymphomas, and 8 reactive lymph

187 The most common subtypes were extranodal marginal-zone lymphoma (EMZL) (37% [n = 32]),

188 The findings were consistent with extranodal marginal-zone lymphoma of the MALT.

189 The findings were most consistent with extranodal marginal-zone lymphoma of the mucosa-associat

190 patients were alive and disease free without extranodal metastasis (median follow-up, 32.5 months).

191 stromal cells promotes CRC tumor growth and extranodal metastasis (P < 0.001).

192 Co-TICs showed increased tumor formation and extranodal metastasis capacities compared to unseparated

193 the LN stromal microenvironment in human CRC extranodal metastasis.

194 factors are lymph node (LN) involvement and extranodal metastasis.

195 ons may lead to effective therapy to prevent extranodal metastasis.

196 d HK cell support of CRC tumor formation and extranodal metastasis.

197 3) Extranodal mucosa associated lymphoid tissue lymphomas a

198 by DNA mutations or deletions in a panel of extranodal MZL (EMZL), nodal MZL (NMZL), and splenic MZL

199 as confirmed for the subgroup of splenic and extranodal MZLs.

200 Our series included nodal (n = 151), extranodal (n = 28), and primary splenic (n = 27) MCL ca

201 ic Islanders had a higher incidence of AITL, extranodal nasal-type natural killer/T-cell lymphoma and

202 Extranodal natural killer (NK) T-cell lymphoma (ENKTL) i

203 r overall survival of 55%, 95% CI 46-65) and extranodal natural killer T-cell lymphoma (108 deaths an

204 The clinical outcome of extranodal natural killer T-cell lymphoma (ENKTL) has im

205 Extranodal natural killer T-cell lymphoma (NKTCL), nasal

206 Extranodal natural killer T-cell lymphoma (NKTCL; nasal

207 ce of adult T-cell leukaemia or lymphoma and extranodal natural killer T-cell lymphoma.

208 enomic changes in blastic natural killer and extranodal natural killer-like T cell lymphoma with cuta

209 Extranodal natural killer-T-cell lymphoma (NKTCL) of nas

210 %) had anaplastic large cell; and 1 each had extranodal natural killer/T cell, angioimmunoblastic, an

211 Extranodal natural killer/T-cell lymphoma (ENKTL), nasal

212 anaplastic large-cell lymphoma (n = 2), and extranodal natural killer/T-cell lymphoma (n = 2).

213 Extranodal natural killer/T-cell lymphoma (NKTCL) is an

214 thophysiology of different cancers including extranodal natural killer/T-cell lymphoma (NKTL).

215 arcinoma (SIR, 16.2; 95% CI, 14.5-18.1), and extranodal natural killer/T-cell lymphoma (SIR, 44.3; 95

216 Extranodal natural killer/T-cell lymphoma rarely present

217 e in the management of mycosis fungoides and extranodal natural killer/T-cell lymphoma.

218 Extranodal natural-killer/T-cell lymphoma (ENKTL) is a r

219 ncy is different from that of other forms of extranodal NHL.

220 ntially critical role in the pathobiology of extranodal NK/T-cell lymphoma and aggressive NK-cell leu

221 ma, 14 adult T-cell leukemia/lymphoma and 44 extranodal NK/T-cell lymphoma that were further separate

222 Extranodal NK/T-cell NHL was also more common in CSA (P

223 -wide association study of 189 patients with extranodal NKTCL, nasal type (WHO classification criteri

224 Central nervous system (CNS) lymphoma is an extranodal non-Hodgkin B-cell lymphoma characterized by

225 inal tract and are the most common subset of extranodal non-Hodgkin lymphoma (NHL).

226 imary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confin

227 Cutaneous T-cell lymphoma (CTCL) is an extranodal non-Hodgkin lymphoma with an adverse prognosi

228 ue (MALT) B-cell lymphoma is the most common extranodal non-Hodgkin lymphoma.

229 rointestinal tract is sa well-known site for extranodal Non-Hodgkin lymphomas, with the stomach is kn

230 ry CNS lymphoma (PCNSL), an uncommon form of extranodal non-Hodgkin's lymphoma (NHL), has increased i

231 An unusual case of primary extranodal non-Hodgkin's lymphoma is described.

232 al nervous system lymphoma is a rare form of extranodal non-Hodgkin's lymphoma that is confined to th

233 On multivariate analysis, extranodal nonbone marrow disease and performance status

234 univariate analysis, bulky disease (>10 cm), extranodal nonbone marrow involvement, and poor performa

235 active lymphoid hyperplasia; (2) polymorphic extranodal or (3) polymorphic nodal lymphoproliferative

236 nlargement, 28% splenic involvement, and 81% extranodal or extrasplenic involvement.

237 gh lactate dehydrogenase, and involvement of extranodal organs (including the central nervous system

238 Overall, 69% extranodal patients and 68% nodal patients received RT.

239 munochemotherapy PET results may help select extranodal patients for consolidation RT.

240 and PFS (HR, 0.35; 95% CI, 0.18-0.69) in the extranodal population; however, the benefit was no longe

241 Extranodal presentation was observed in 224 (66%) patien

242 e an aggressive clinical course and frequent extranodal presentation.

243 ng that REL amplification is associated with extranodal presentation.

244 substrate of AVNR during both intranodal and extranodal reentry.

245 ral, supraclavicular, internal mammary), and extranodal regions was documented.

246 nt natural history with frequent, continuous extranodal relapses.

247 involvement were involvement of more than 1 extranodal site (hazard ratio [HR], 2.60; 95% confidence

248 0037), involvement of more than one extranodal site (P = .0000), poor performance status (P

249 identified only involvement of more than one extranodal site (P = .0005) and an increased LDH (P = .0

250 Serum LDH and involvement of more than one extranodal site are independent risk factors for CNS rec

251 More than one extranodal site of disease and a second-line age-adjuste

252 bulk (elevated lactate dehydrogenase and >1 extranodal site), we built a simple risk model that coul

253 COG) performance status (PS) 2 to 4, 23%; >1 extranodal site, 43%; advanced stage, 78%; and central n

254 s (ECOG PS) >=2, stage III or IV disease, >1 extranodal site, elevated lactate dehydrogenase, Interna

255 Cancer Oncology Group performance status >1, extranodal sites >1, elevated lactate dehydrogenase, and

256 isease, lactic dehydrogenase (LDH) > normal, extranodal sites (ENSs) > one, and performance status (P

257 ent (P = .0005), the presence of one or more extranodal sites (P = .005), both nodal and extranodal d

258 present in 30 patients (86%), with multiple extranodal sites (two to seven) in 18 (51%).

259 ave a predilection for remaining confined to extranodal sites and strong CNS tropism.

260 The number of extranodal sites and the International Prognostic Index

261 Results: For nodal and extranodal sites combined, corrected staging (18)F-FDG P

262 Malignant lymphomas within inflamed extranodal sites exhibit a relatively high incidence of

263 Lymphoma arises at extranodal sites in which a pre-existing inflammatory re

264 Fifty-seven involved diverse extranodal sites including 14 stomach, 11 lung, 7 orbit,

265 it was recently reported that the number of extranodal sites is a more reliable predictor of CNS dis

266 ic phenotype associated with colonization of extranodal sites leads to CNS spread, possibly related t

267 ells that interact with malignant B cells at extranodal sites may influence both the development and

268 cology Group (ECOG) scale, more than 1, 23%; extranodal sites more than 1, 29%; mass more than 10 cm,

269 , serum lactate dehydrogenase, and number of extranodal sites of disease are all important prognostic

270 Only the number of extranodal sites was associated with occult CSF lymphoma

271 logy Group performance status, and number of extranodal sites were confirmed to be significant variab

272 Extranodal sites were involved in 14 cases (35%).

273 oup [ECOG] performance status, and number of extranodal sites) (P < 0.0001).

274 e dehydrogenase concentration, and number of extranodal sites), prognostic gene signatures have recen

275 llow-up, 22% of patients relapsed, mainly in extranodal sites, and 4% transformed to diffuse large B-

276 dehydrogenase, performance status, number of extranodal sites, and age, as previously reported.

277 marrow (BM), spleen, bulky lymph nodes, and extranodal sites, and in patients who had relapsed follo

278 mance score, lactic dehydrogenase, number of extranodal sites, B symptoms, size of largest mass, and

279 ersally involves the lungs with other common extranodal sites, including skin, central nervous system

280 which frequently involve the skin and other extranodal sites, is often problematic because of the di

281 Age, stage, sex, B symptoms, number of extranodal sites, lactate dehydrogenase (LDH) levels, er

282 ancy has been increasingly observed in other extranodal sites, particularly in the skin.

283 (PMLCL) has a high propensity for involving extranodal sites, we investigated the frequency and patt

284 ), 91% were stage 4, and 69% had two or more extranodal sites.

285 pu in the development of AIDS-NHL at EC-rich extranodal sites.

286 eneous disease that occurs in both nodal and extranodal sites.

287 that are induced by chronic inflammation in extranodal sites.

288 ficantly enriched in patients with 2 or more extranodal sites.

289 polymorphic disease, and the involvement of extranodal sites.

290 V-positive histology, and the involvement of extranodal sites.

291 volvement; extranodal involvement; number of extranodal sites; specific sites: bone marrow, liver, ki

292 High-risk features include extranodal spread of melanoma, more than two positive ly

293 Extranodal stage I DLBCL had a worse outcome than nodal

294 d should be in the differential diagnosis of extranodal T-cell lymphoproliferations, including those

295 These cells accumulated in extranodal tissues and gave rise to clonal tumors recapi

296 Non-Hodgkin's lymphoma may arise in extranodal tissues within the head and neck region.

297 ization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transfo

298 ymphoid organs, but disseminates early on in extranodal tissues.

299 hree possible disease forms in each patient: extranodal tumor, lymphadenopathy, and ascites.

300 Nodal and extranodal UECT and CECT findings were classified accord